EGFR mutation analysis from REASON: A registry for the epidemiologic and scientific evaluation of EGFR mutation status in newly diagnosed NSCLC patients stage IIIB/IV.

被引：0
|
作者：
Schuette, Wolfgang
Eberhardt, Wilfried Ernst Erich
von der Schulenburg, J. -Mathias Graf
Dietel, Manfred
Schirmacher, Peter
Zaun, Silke
Thomas, Michael
机构：
[1] Hosp Martha Maria Halle Doelau, Halle, Germany
[2] Innere Klin & Poliklin Tumorforsch, Essen, Germany
[3] Leibniz Univ Hannover, Forsch Stelle Fuer Gesundheitsoekon, D-30167 Hannover, Germany
[4] Charite, Pathol Inst, Berlin, Germany
[5] Univ Dept Pathol, Heidelberg, Germany
[6] AstraZeneca, Wedel, Germany
[7] Heidelberg Univ, Thoraxklin, Heidelberg, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e18016
引用
收藏
页数：1
相关论文
共 50 条
  • [31] A phase IIIb open-label study of afatinib in EGFR TKI-naive patients (pts) with EGFR mutation-positive (EGFRm1) NSCLC: Exploratory biomarker analysis
    Wang, J.
    Zhao, J.
    Bai, H.
    Wang, X.
    Wang, Y.
    Duan, J.
    Chen, H.
    Meng, S.
    Tian, Y.
    Huang, D. C-L.
    Wu, Y-L.
    [J]. ANNALS OF ONCOLOGY, 2019, 30
  • [32] Analysis of EGFR mutation status in malignant pleural effusion and plasma from patients with advanced lung adenocarcinoma
    Son, Seung-Myoung
    Woo, Chang Gok
    Han, Hye Sook
    Lee, Ki Hyeong
    Lim, Young Hyun
    Lee, Ok-Jun
    [J]. CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2020, 58 (09) : 1547 - 1555
  • [33] Validation of Cell-Free DNA Collection Tubes for Determination of EGFR Mutation Status in Liquid Biopsy from NSCLC Patients
    Marta Sesé
    Rosa Somoza
    Inmaculada Maestu
    Maria Martín Ureste
    Alfredo Sanchez
    Juan Felipe Cordoba
    Irene Sansano
    Griselda Venturas
    Santiago Ramón y Cajal
    Javier Hernández-Losa
    [J]. Oncology and Therapy, 2019, 7 : 131 - 139
  • [34] Validation of Cell-Free DNA Collection Tubes for Determination of EGFR Mutation Status in Liquid Biopsy from NSCLC Patients
    Sese, Marta
    Somoza, Rosa
    Maestu, Inmaculada
    Martin Ureste, Maria
    Sanchez, Alfredo
    Felipe Cordoba, Juan
    Sansano, Irene
    Venturas, Griselda
    Ramon y Cajal, Santiago
    Hernandez-Losa, Javier
    [J]. ONCOLOGY AND THERAPY, 2019, 7 (02) : 131 - 139
  • [35] A phase II trial of IPI-504 (retaspimycin hydrochloride), a novel Hsp90 inhibitor, in patients with relapsed and/or refractory stage IIIb or stage IV non-small cell lung cancer (NSCLC) stratified by EGFR mutation status
    Sequist, L. V.
    Gettinger, S.
    Natale, R.
    Martins, R.
    Lilenbaum, R.
    Jaenne, P.
    Gray, J.
    Samuel, T. A.
    Grayzel, D.
    Lynch, T. J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [36] Next-generation sequencing of Chinese stage IV lung cancer patients reveals an association between EGFR mutation status and survival outcome
    Li, F.
    Du, X.
    Zhang, H.
    Ju, T.
    Chen, C.
    Qu, Q.
    Zhang, X.
    Qi, L.
    Lizee, G.
    [J]. CLINICAL GENETICS, 2017, 91 (03) : 488 - 493
  • [37] Prediction of EGFR mutation status through radiomic features from 18F FDG PET/CT in NSCLC cohort of patients
    Monaco, L.
    De Bernardi, E.
    Bertola, F.
    Bono, F.
    Casati, G.
    Cortinovis, D.
    Crivellaro, C.
    Elisei, F.
    L'Imperio, V.
    Landoni, C.
    Pagni, F.
    Turolla, E.
    Messa, C.
    Guerra, L.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (SUPPL 1) : S468 - S468
  • [38] Relationship between EGFR Mutation Status and Response to Specific Chemotherapeutic Agents in Patients with Stage IV Non-Small Cell Lung Cancer
    Ernani, Vinicius
    Chatwal, Monica S.
    Kumar, Mukesh
    Zhang, Chao
    Chen, Zhengjia
    Owonikoko, Taofeek K.
    Ramalingam, Suresh S.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S525 - S525
  • [39] Long term survival analysis of osimertinib in stage IV NSCLC patients harbored acquired EGFR T790M mutation: A real-word study in China
    Wang, S.
    Han, B.
    [J]. ANNALS OF ONCOLOGY, 2019, 30
  • [40] SYSTEMATIC DETERMINATION OF EGFR MUTATION (M) AND IMMUNOHISTOCHEMISTRY (IHC) OF ALK TRANSLOCATION (T) STATUS IN PATIENTS (P) WITH NEWLY NON SMALL CELL LUNG CANCER (NSCLC)
    Ponce Aix, S.
    Zugazagoitia, J.
    Blazquez Arroyo, M.
    Ruiz Ares, G.
    Nunez Sobrino, J. A.
    Iglesias Docampo, L. C.
    Manneh Kopp, R. A.
    Garcia Martin, R. M.
    Rodriguez Peralto, J. L.
    Enguita Valls, A. B.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (04) : S9 - S9
12345